Antibody/T-cell receptor chimeric constructs and uses thereof

Patent metadata

Field	Value
Publication number	US-10822389-B2
Application number	US-201916667781-A
Country	US
Kind code	B2
Filing date	Oct 29, 2019
Priority date	Oct 23, 2015
Publication date	Nov 3, 2020
Grant date	Nov 3, 2020

Abstract

The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

First claim

What is claimed is:

1. An antibody-T cell receptor (TCR) chimeric molecule (abTCR) that specifically binds to a target antigen, comprising:
a) a first polypeptide chain comprising a first antigen-binding domain comprising a V H antibody domain and a first T cell receptor domain (TCRD) comprising a first transmembrane domain of a first TCR subunit; and
b) a second polypeptide chain comprising a second antigen-binding domain comprising a V L antibody domain and a second TCRD comprising a second transmembrane domain of a second TCR subunit,
wherein the V H domain of the first antigen-binding domain and the V L domain of the second antigen-binding domain form an antigen-binding module that specifically binds to the target antigen,
wherein the first TCRD and the second TCRD form a T cell receptor module (TCRM) that is capable of recruiting at least one TCR-associated signaling module,
wherein the target antigen is a complex comprising a peptide and an MHC protein, and
wherein:
(i) the first TCR subunit is a TCR α chain, and the second TCR subunit is a TCR β chain;
(ii) the first TCR subunit is a TCR β chain, and the second TCR subunit is a TCR α chain;
(iii) the first TCR subunit is a TCR γ chain, and the second TCR subunit is a TCR δ chain; or
(iv) the first TCR subunit is a TCR δ chain, and the second TCR subunit is a TCR γ chain.

2. The abTCR of claim 1 , wherein the first polypeptide chain further comprises a first peptide linker between the first antigen-binding domain and the first TCRD, and the second polypeptide chain further comprises a second peptide linker between the second antigen-binding domain and the second TCRD.

3. The abTCR of claim 2 , wherein the first and/or second peptide linkers comprise, individually, a constant domain or fragment thereof from an immunoglobulin or T cell receptor subunit.

4. The abTCR of claim 3 , wherein the first and/or second peptide linkers comprise, individually, a CH1, CH2, CH3, CH4 or CL antibody domain, or a fragment thereof.

5. The abTCR of claim 3 , wherein the first and/or second peptide linkers comprise, individually, a Cα, Cβ, Cγ, or Cδ TCR domain, or a fragment thereof.

6. The abTCR of claim 1 , wherein the first TCRD further comprises a first connecting peptide or fragment thereof of a TCR subunit N-terminal to the first transmembrane domain; and/or wherein the second TCRD further comprises a second connecting peptide or fragment thereof of a TCR subunit N-terminal to the second transmembrane domain.

7. The abTCR of claim 1 , wherein the first TCRD further comprises a first TCR intracellular domain comprising a TCR intracellular sequence C-terminal to the first transmembrane domain; and/or wherein the second TCRD further comprises a second TCR intracellular domain comprising a TCR intracellular sequence C-terminal to the second transmembrane domain.

8. The abTCR of claim 1 , wherein the first polypeptide chain further comprises a first accessory intracellular domain comprising a co-stimulatory intracellular signaling sequence C-terminal to the first transmembrane domain; and/or wherein the second polypeptide chain further comprises a second accessory intracellular domain comprising a co-stimulatory intracellular signaling sequence C-terminal to the second transmembrane domain.

9. The abTCR of claim 1 , wherein the peptide in the target antigen complex is derived from a protein selected from the group consisting of WT-1, AFP, HPV16-E7, NY-ESO-1, PRAME, EBV-LMP2A, HIV-1, and PSA.

10. The abTCR of claim 1 , wherein the TCR-associated signaling module is selected from the group consisting of CD3δε, CD3γε, and ζζ.

11. Nucleic acid(s) encoding the first and second polypeptide chains of the abTCR of claim 1 .

12. An effector cell presenting on its surface the abTCR of claim 1 .

13. The effector cell of claim 12 , wherein the effector cell does not express the first TCR subunit and/or the second TCR subunit.

14. The effector cell of claim 12 , wherein effector cell is modified to block or decrease the expression of a first endogenous TCR subunit and/or a second endogenous TCR subunit.

15. A method of killing a target cell presenting a target antigen, comprising contacting the target cell with the effector cell of claim 12 , wherein the abTCR specifically binds to the target antigen.

16. A pharmaceutical composition comprising the effector cell of claim 12 , and a pharmaceutically acceptable carrier.

17. A method of treating a target antigen-associated disease in an individual in need thereof comprising administering to the individual an effective amount of the pharmaceutical composition of claim 16 .

18. The method of claim 17 , wherein the target antigen-associated disease is a cancer.

19. The method of claim 18 , wherein the cancer comprises a solid tumor.

20. The method of claim 19 , wherein the cancer is selected from the group consisting of adrenocortical carcinoma, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancers, esophageal cancer, glioblastoma, glioma, hepatocellular carcinoma, head and neck cancer, kidney cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, pheochromocytoma, plasmacytoma, neuroblastoma, ovarian cancer, prostate cancer, sarcoma, stomach cancer, uterine cancer and thyroid cancer.

21. The method of claim 17 , wherein the target antigen-associated disease is a viral infection.

22. The method of claim 21 , wherein the viral infection is caused by a virus selected from the group consisting of Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B Virus (HBV), Kaposi's Sarcoma associated herpesvirus (KSHV), Human papillomavirus (HPV), Molluscum contagiosum virus (MCV), Human T cell leukemia virus 1 (HTLV-1), HIV (Human immunodeficiency virus), and Hepatitis C Virus (HCV).

Assignees

• Eureka Therapeutics Inc

Inventors

• Lu Jingwei
• Yang Zhiyuan
• Liu Cheng
• Liu Hong
• Xu Yiyang
• Yan Su
• Chan Vivien Wai-Fan
• Horan Lucas

Classifications

• C07K2319/02

  containing a signal sequence · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K40/4211

  CD19 or B4 · CPC title